Latest Pharma Insights
Priothera Seeks Partner As Mocravimod Advances In Phase III Leukemia Trial
The timelines for the MO-TRANS trial of the sphingosine 1 phosphate receptor modulator have been pushed back as the number of patients enrolled increased significantly but that ‘puts us in the strongest position to generate robust Phase III data,’ CEO Florent Gros tells Scrip.
Scrip - September 9, 2026
The timelines for the MO-TRANS trial of the sphingosine 1 phosphate receptor modulator have been pushed back as the number of patients enrolled increased significantly but that ‘puts us in the strongest position to generate robust Phase III data,’ CEO Florent Gros tells Scrip.
Scrip - September 9, 2026
Boston Scientific Says Cyberattack Makes 2026 Guidance ‘Unlikely’ To Be Met
The medical device maker says an Aug. 25 cyberattack makes 2026 guidance “unlikely” to be met, sending shares down 5.9%, in a year already marked by a Watchman slowdown.
Medtech Insight - September 9, 2026
The medical device maker says an Aug. 25 cyberattack makes 2026 guidance “unlikely” to be met, sending shares down 5.9%, in a year already marked by a Watchman slowdown.
Medtech Insight - September 9, 2026
Evommune Scraps Second EVO756 Program But Presses On In Migraine
After two Phase IIb setbacks for EVO756, Evommune turns its AD focus to EVO301 while advancing the MRGPRX2 antagonist in migraine.
Scrip - September 9, 2026
After two Phase IIb setbacks for EVO756, Evommune turns its AD focus to EVO301 while advancing the MRGPRX2 antagonist in migraine.
Scrip - September 9, 2026
Structure’s Oral Amylin Shows Early Promise In First Human Test
Structure's oral amylin ACCG-2671 drove up to 3.3% weight loss in its first human trial, but dose-related nausea and a modest headline number sent shares down 14.7%.
Scrip - September 9, 2026
Structure's oral amylin ACCG-2671 drove up to 3.3% weight loss in its first human trial, but dose-related nausea and a modest headline number sent shares down 14.7%.
Scrip - September 9, 2026
ChrysCapital’s NIL Bags Minipress XL, Steps Into Ophthalmology In Rapid Deal Burst
ChrysCapital controlled Novartis India Ltd, which is being renamed as Evonile Pharma, seals back-to-back deals, picking up Pfizer's Minipress XL brand and locking in distribution rights for Novartis's ranibizumab and brolucizumab in India.
Scrip - September 9, 2026
ChrysCapital controlled Novartis India Ltd, which is being renamed as Evonile Pharma, seals back-to-back deals, picking up Pfizer's Minipress XL brand and locking in distribution rights for Novartis's ranibizumab and brolucizumab in India.
Scrip - September 9, 2026
The Company Betting It Can Simulate A Human Body
Deep Origin claims that in silico models can one day replace animal testing, and has published wet lab results to argue the models already work. It has also publicly committed to never developing a pipeline.
In Vivo - September 9, 2026
Deep Origin claims that in silico models can one day replace animal testing, and has published wet lab results to argue the models already work. It has also publicly committed to never developing a pipeline.
In Vivo - September 9, 2026
UpFront’s Finger-Prick Stroke Blood Test Gets First-Of-Its-Kind CE Mark
Company says combination of novel biomarkers can detect large vessel occlusion stroke in under 10 minutes.
Medtech Insight - September 9, 2026
Company says combination of novel biomarkers can detect large vessel occlusion stroke in under 10 minutes.
Medtech Insight - September 9, 2026
Priothera Seeks Partner As Mocravimod Advances In Phase III Leukemia Trial
The timelines for the MO-TRANS trial of the sphingosine 1 phosphate receptor modulator have been pushed back as the number of patients enrolled increased significantly but that ‘puts us in the strongest position to generate robust Phase III data,’ CEO Florent Gros tells Scrip.
Scrip - September 9, 2026
The timelines for the MO-TRANS trial of the sphingosine 1 phosphate receptor modulator have been pushed back as the number of patients enrolled increased significantly but that ‘puts us in the strongest position to generate robust Phase III data,’ CEO Florent Gros tells Scrip.
Scrip - September 9, 2026
Evommune Scraps Second EVO756 Program But Presses On In Migraine
After two Phase IIb setbacks for EVO756, Evommune turns its AD focus to EVO301 while advancing the MRGPRX2 antagonist in migraine.
Scrip - September 9, 2026
After two Phase IIb setbacks for EVO756, Evommune turns its AD focus to EVO301 while advancing the MRGPRX2 antagonist in migraine.
Scrip - September 9, 2026
Structure’s Oral Amylin Shows Early Promise In First Human Test
Structure's oral amylin ACCG-2671 drove up to 3.3% weight loss in its first human trial, but dose-related nausea and a modest headline number sent shares down 14.7%.
Scrip - September 9, 2026
Structure's oral amylin ACCG-2671 drove up to 3.3% weight loss in its first human trial, but dose-related nausea and a modest headline number sent shares down 14.7%.
Scrip - September 9, 2026
ChrysCapital’s NIL Bags Minipress XL, Steps Into Ophthalmology In Rapid Deal Burst
ChrysCapital controlled Novartis India Ltd, which is being renamed as Evonile Pharma, seals back-to-back deals, picking up Pfizer's Minipress XL brand and locking in distribution rights for Novartis's ranibizumab and brolucizumab in India.
Scrip - September 9, 2026
ChrysCapital controlled Novartis India Ltd, which is being renamed as Evonile Pharma, seals back-to-back deals, picking up Pfizer's Minipress XL brand and locking in distribution rights for Novartis's ranibizumab and brolucizumab in India.
Scrip - September 9, 2026
Boston Scientific Says Cyberattack Makes 2026 Guidance ‘Unlikely’ To Be Met
The medical device maker says an Aug. 25 cyberattack makes 2026 guidance “unlikely” to be met, sending shares down 5.9%, in a year already marked by a Watchman slowdown.
Medtech Insight - September 9, 2026
The medical device maker says an Aug. 25 cyberattack makes 2026 guidance “unlikely” to be met, sending shares down 5.9%, in a year already marked by a Watchman slowdown.
Medtech Insight - September 9, 2026
UpFront’s Finger-Prick Stroke Blood Test Gets First-Of-Its-Kind CE Mark
Company says combination of novel biomarkers can detect large vessel occlusion stroke in under 10 minutes.
Medtech Insight - September 9, 2026
Company says combination of novel biomarkers can detect large vessel occlusion stroke in under 10 minutes.
Medtech Insight - September 9, 2026
PCPC Pays Tribute to Peter Barton Hutt, Architect of US Cosmetics Regulation; Exec Roundup
The Personal Care Products Council said Peter Barton Hutt's enduring legacy will be felt throughout its organization, through the institutions and the industry he helped shape; Executive Roundup
HBW Insight - September 8, 2026
The Personal Care Products Council said Peter Barton Hutt's enduring legacy will be felt throughout its organization, through the institutions and the industry he helped shape; Executive Roundup
HBW Insight - September 8, 2026
If Alexa Won’t Recommend You, ‘You’re Invisible’: How Amazon’s New AI Tool Is Shaking Up OTC
Amazon's integration of AI into its shopping experience is set to fundamentally alter how consumers discover and choose consumer health products. Ross Barber of World Products argues that brands competing only for search rankings are already playing yesterday's game.
HBW Insight - September 8, 2026
Amazon's integration of AI into its shopping experience is set to fundamentally alter how consumers discover and choose consumer health products. Ross Barber of World Products argues that brands competing only for search rankings are already playing yesterday's game.
HBW Insight - September 8, 2026
Get To Know: Indian Wellness Tech Licensing Specialist Boudhik Ventures
Q&A with Boudhik Ventures director Ishan Tiwari on the Indian firm's mandate-driven model and its push to license Renavita, a patented kidney wellness formulation, in the UK and Europe.
HBW Insight - September 8, 2026
Q&A with Boudhik Ventures director Ishan Tiwari on the Indian firm's mandate-driven model and its push to license Renavita, a patented kidney wellness formulation, in the UK and Europe.
HBW Insight - September 8, 2026
Fresenius Kabi Latest To Launch Generic Bridion As Merck Prepares US Market Exit
Fresenius Kabi has launched a pre-filled syringe generic sugammadex in the US, as growing generic competition drives Merck to anticipate discontinuing US Bridion sales.
Generics Bulletin - September 8, 2026
Fresenius Kabi has launched a pre-filled syringe generic sugammadex in the US, as growing generic competition drives Merck to anticipate discontinuing US Bridion sales.
Generics Bulletin - September 8, 2026
Biocon Locks In 10-Year Pertuzumab Opportunity In Brazil
Biocon has secured a 10-year route into Brazil’s public pertuzumab market through a Productive Development Partnership program that combines exclusive access with phased localization and technology transfer for the Perjeta biosimilar.
Generics Bulletin - September 8, 2026
Biocon has secured a 10-year route into Brazil’s public pertuzumab market through a Productive Development Partnership program that combines exclusive access with phased localization and technology transfer for the Perjeta biosimilar.
Generics Bulletin - September 8, 2026
‘It’s Time To Put The Muttering To Rest’ – Samsung Bioepis Rebuts Biosimilar Drift Concerns
Following the publication of their co-authored journal article on why product drift is not an issue for biosimilars, Samsung Bioepis executives Gillian Woollett and Joseph Park explain why they felt the longstanding issue needed to be put to rest.
Generics Bulletin - September 8, 2026
Following the publication of their co-authored journal article on why product drift is not an issue for biosimilars, Samsung Bioepis executives Gillian Woollett and Joseph Park explain why they felt the longstanding issue needed to be put to rest.
Generics Bulletin - September 8, 2026
Accord Pins Denosumab Launch Delay On Q-Code Timing
Accord says securing a Q-code was the decisive factor behind the delayed US launch of Osvyrti and Jubereq, which reached the market around nine months after a legal sales restriction expired.
Generics Bulletin - September 8, 2026
Accord says securing a Q-code was the decisive factor behind the delayed US launch of Osvyrti and Jubereq, which reached the market around nine months after a legal sales restriction expired.
Generics Bulletin - September 8, 2026
The Company Betting It Can Simulate A Human Body
Deep Origin claims that in silico models can one day replace animal testing, and has published wet lab results to argue the models already work. It has also publicly committed to never developing a pipeline.
In Vivo - September 9, 2026
Deep Origin claims that in silico models can one day replace animal testing, and has published wet lab results to argue the models already work. It has also publicly committed to never developing a pipeline.
In Vivo - September 9, 2026